DS
ZVRA icon

David Shaw’s Zevra Therapeutics ZVRA Stock Holding History

David Shaw’s Portfolio ZVRA Stock Details ZVRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$18.7M Buy
1,306,949
+460,492
+54% +$5.12M 0.01% 1325
2026
Q1 		$7.89M Sell
846,457
-17,289
-2% -$156K ﹤0.01% 1821
2025
Q4 		$7.74M Buy
863,746
+137,916
+19% +$1.3M ﹤0.01% 1968
2025
Q3 		$6.9M Buy
725,830
+536,517
+283% +$5.38M ﹤0.01% 1954
2025
Q2 		$1.67M Buy
189,313
+161,943
+592% +$1.31M ﹤0.01% 2873
2025
Q1 		$205K Buy
27,370
+2,295
+9% +$18.2K ﹤0.01% 3924
2024
Q4 		$209K Buy
+25,075
New +$214K ﹤0.01% 4065
2022
Q2 		– Sell
-10,453
Closed -$53K – 5840
2022
Q1 		$53K Sell
10,453
-13,356
-56% -$85K ﹤0.01% 5132
2021
Q4 		$207K Buy
+23,809
New +$212K ﹤0.01% 4867

Other funds holding ZVRA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return

David Shaw's ZVRA Position: Q2 2026 in Review

David Shaw increased its Zevra Therapeutics (ZVRA) stake by 54% in Q2 2026, buying an estimated $5.12M and bringing the position to 1,306,949 shares worth $18.7M. The position accounts for 0.01% of the portfolio, ranked #1325.

David Shaw first reported a position in ZVRA in Q4 2021 and has held it in 9 quarters since. 156 funds tracked by Wall St. Rank hold ZVRA as of Q2 2026.

  • David Shaw held 1,306,949 shares of Zevra Therapeutics worth $18.7M as of Q2 2026.
  • David Shaw bought 460,492 Zevra Therapeutics shares in Q2 2026, an estimated $5.12M.
  • Zevra Therapeutics made up 0.01% of David Shaw's portfolio in Q2 2026, its #1325 holding.
  • David Shaw first reported a position in Zevra Therapeutics in Q4 2021 and has held it in 9 quarters since.
  • 156 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.